Lake Street Capital Initiates Coverage on LifeVantage (NASDAQ:LFVN)

Lake Street Capital assumed coverage on shares of LifeVantage (NASDAQ:LFVN) in a report released on Thursday, Marketbeat.com reports. The firm issued a buy rating and a $26.00 price objective on the stock.

LifeVantage Price Performance

Shares of NASDAQ:LFVN opened at $17.36 on Thursday. The business has a fifty day moving average price of $13.99 and a 200-day moving average price of $10.32. The company has a market capitalization of $217.43 million, a PE ratio of 54.25 and a beta of 0.87. LifeVantage has a 1-year low of $5.22 and a 1-year high of $18.41.

LifeVantage (NASDAQ:LFVN) last released its quarterly earnings data on Tuesday, October 29th. The company reported $0.15 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.15. The business had revenue of $47.21 million during the quarter. LifeVantage had a net margin of 2.11% and a return on equity of 29.24%.

LifeVantage Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, December 16th. Shareholders of record on Monday, December 2nd were paid a dividend of $0.04 per share. The ex-dividend date of this dividend was Monday, December 2nd. This represents a $0.16 annualized dividend and a yield of 0.92%. LifeVantage’s dividend payout ratio is 50.00%.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of LFVN. Renaissance Technologies LLC increased its holdings in LifeVantage by 2.1% in the 2nd quarter. Renaissance Technologies LLC now owns 855,118 shares of the company’s stock worth $5,490,000 after buying an additional 17,300 shares in the last quarter. Capital Management Corp VA purchased a new stake in shares of LifeVantage during the 3rd quarter valued at about $5,073,000. HighTower Advisors LLC bought a new stake in shares of LifeVantage in the third quarter worth approximately $638,000. Barclays PLC raised its holdings in shares of LifeVantage by 38.2% during the third quarter. Barclays PLC now owns 41,966 shares of the company’s stock valued at $507,000 after purchasing an additional 11,608 shares during the last quarter. Finally, Ritholtz Wealth Management lifted its position in LifeVantage by 62.0% during the third quarter. Ritholtz Wealth Management now owns 28,666 shares of the company’s stock valued at $346,000 after purchasing an additional 10,974 shares during the period. Hedge funds and other institutional investors own 35.32% of the company’s stock.

LifeVantage Company Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.